<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083833</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-TQT-101</org_study_id>
    <nct_id>NCT04083833</nct_id>
  </id_info>
  <brief_title>A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wex Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wex Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if a single subcutaneous (SC) administration of TTX at various dose levels has&#xD;
      an effect on the QT/QTc intervals when assessing concentration QT (C-QT) relationship (i.e.,&#xD;
      QT/QTc intervals prolongation in relation to plasma levels of TTX) in healthy adult subjects.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        1. To determine if a single SC administration of TTX at various dose levels has an effect&#xD;
           on other important electrocardiogram (ECG) parameters in healthy adult subjects.&#xD;
&#xD;
        2. To demonstrate sensitivity of this QTc assay using moxifloxacin as a positive control.&#xD;
&#xD;
        3. To confirm plasma pharmacokinetic (PK) of a single SC administration of TTX at various&#xD;
           dose levels when administered to healthy adult subjects.&#xD;
&#xD;
        4. To determine the overall safety and tolerability of a single SC administration of TTX at&#xD;
           various dose levels when administered to healthy adult subjects.&#xD;
&#xD;
      Test Product, Dose, Duration, Mode of Administration, and Batch Number:&#xD;
&#xD;
      The test product was 30 µg/mL tetrodotoxin (TTX) for injection, Lot No. F141124-001.&#xD;
&#xD;
      Subjects were also administered:&#xD;
&#xD;
        -  Tetrodotoxin matching placebo a sterile 0.9% sodium chloride injection or normal saline&#xD;
           for injection, Lot No. 84-093-DK&#xD;
&#xD;
        -  400 mg Avelox® (moxifloxacin hydrochloride) tablets, Lot No. BXHJ1S1&#xD;
&#xD;
        -  Moxifloxacin matching placebo film-coated tablets, Id.-No.: K15372, Batch No.: C1606007&#xD;
&#xD;
      Treatments were as follows:&#xD;
&#xD;
      Treatment Arm (n = 9)&#xD;
&#xD;
      Treatment A:&#xD;
&#xD;
      (Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution)&#xD;
      administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo&#xD;
      tablet)&#xD;
&#xD;
      Treatment B:&#xD;
&#xD;
      (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered&#xD;
      as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet)&#xD;
&#xD;
      Treatment C:&#xD;
&#xD;
      (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution)&#xD;
      administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo&#xD;
      tablet)&#xD;
&#xD;
      Subjects randomized to the Control Arm were further randomized to receive 1 of 2 treatment&#xD;
      sequences (Treatment Sequence DEF [n = 8] and Treatment Sequence GHI [n = 8]):&#xD;
&#xD;
      Control Arm (n = 16)&#xD;
&#xD;
      Treatment D:&#xD;
&#xD;
      (Period 1) A single matching-TTX placebo (0.5 mL of placebo injection solution) administered&#xD;
      as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet)&#xD;
&#xD;
      Treatment E:&#xD;
&#xD;
      (Period 2) A single matching-TTX placebo (1 mL of placebo injection solution) administered as&#xD;
      1 SC injection with a single oral 400 mg moxifloxacin (1 x 400 mg tablet)&#xD;
&#xD;
      Treatment F:&#xD;
&#xD;
      (Period 3) A single matching-TTX placebo (1.5 mL of placebo injection solution) administered&#xD;
      as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)&#xD;
&#xD;
      Treatment G:&#xD;
&#xD;
      (Period 1) A single matching-TTX placebo (0.5 mL of placebo injection solution) administered&#xD;
      as 1 SC injection with a single oral 400 mg moxifloxacin (1 x 400 mg tablet)&#xD;
&#xD;
      Treatment H:&#xD;
&#xD;
      (Period 2) A single matching-TTX placebo (1 mL of placebo injection solution) administered as&#xD;
      1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet)&#xD;
&#xD;
      Treatment I:&#xD;
&#xD;
      (Period 3) A single matching-TTX placebo (1.5 mL of placebo injection solution) administered&#xD;
      as 2 SC injections with a single oral 400 mg moxifloxacin (1 x 400 mg tablet) All oral study&#xD;
      drugs were administered with approximately 240 mL of water.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Actual">March 24, 2018</completion_date>
  <primary_completion_date type="Actual">March 24, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiodynamic</measure>
    <time_frame>24 hours</time_frame>
    <description>The primary cardiodynamic endpoint was the effect of TTX plasma concentrations on the QTc interval using linear mixed-effect exposure-response modeling, including the predicted ddQTc at Cmax values corresponding to exposure levels of interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG Paramenters</measure>
    <time_frame>24 hours</time_frame>
    <description>Other ECG parameters such as QTc, QT, PR, and RR intervals, QRS duration, and HR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG Paramenters</measure>
    <time_frame>24 hours</time_frame>
    <description>Abnormalities in T wave morphology and pathologic U waves will be reported when identified by the cardiologist reviewer, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assay Sensitivity</measure>
    <time_frame>24 hours</time_frame>
    <description>3. Assay sensitivity assessment with ddQTc at the geometric mean Cmax value predicted from a linear mixed-effect model evaluating the relationship between QTc and moxifloxacin plasma concentrations (exposure-response modeling).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>TQT Study</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Period 1) A single TTX dose of 15 μg (0.5 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 2) A single TTX dose of 30 μg (1 mL of TTX 30 μg/mL injection solution) administered as 1 SC injection with a single oral moxifloxacin matching placebo (1 x placebo tablet) (Period 3) A single TTX dose of 45 μg (1.5 mL of TTX 30 μg/mL injection solution) administered as 2 SC injections with a single oral moxifloxacin matching placebo (1 x placebo tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment D:&#xD;
(Period 1)A single matching-TTX placebo administered with a single oral moxifloxacin matching placebo&#xD;
Treatment E:&#xD;
(Period 2)A single matching-TTX placebo with a single oral 400 mg moxifloxacin&#xD;
Treatment F:&#xD;
(Period 3)A single matching-TTX placebo with a single oral moxifloxacin matching placebo&#xD;
Treatment G:&#xD;
(Period 1)A single matching-TTX placebo with a single oral 400 mg moxifloxacin&#xD;
Treatment H:&#xD;
(Period 2)A single matching-TTX placebo with a single oral moxifloxacin matching placebo&#xD;
Treatment I:&#xD;
(Period 3)A single matching-TTX placebo with a single oral 400 mg moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrodotoxin</intervention_name>
    <description>A single TTX dose in a dose ascending study</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Halneuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>matching placebo comparator</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, adult, male or female 18 55 years of age, inclusive, at screening.&#xD;
&#xD;
          2. Continuous non smoker who has not used nicotine containing products for at least 3&#xD;
             months prior to the first dose and throughout the study.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.&#xD;
&#xD;
          4. Medically healthy with no clinically significant medical history, physical&#xD;
             examination, neurologic examinations, laboratory profiles, vital signs, or ECGs, as&#xD;
             deemed by the PI or designee.&#xD;
&#xD;
          5. For a female of childbearing potential: either be sexually inactive (abstinent) for 14&#xD;
             days prior to the first dose and throughout the study or be using one of the following&#xD;
             acceptable birth control methods:&#xD;
&#xD;
               -  non-hormone releasing intrauterine device for at least 3 months prior to the&#xD;
                  first dose and throughout the study.&#xD;
&#xD;
               -  surgical sterilization of the partner (vasectomy for 4 months minimum prior to&#xD;
                  the first dose).&#xD;
&#xD;
               -  physical barrier method (e.g., condom, diaphragm) with spermicide for at least 14&#xD;
                  days prior to the first dose and throughout the study.&#xD;
&#xD;
             A female subject who claims to be sexually inactive, but becomes sexually active&#xD;
             during the course of the study must agree to use a physical barrier method (e.g.,&#xD;
             condom, diaphragm) with spermicide from the time of the start of sexual activity and&#xD;
             throughout the study.&#xD;
&#xD;
             In addition, female subjects of childbearing potential will be advised to remain&#xD;
             sexually inactive or to keep the same birth control method for at least 28 days&#xD;
             following the last dose.&#xD;
&#xD;
          6. For a female of non childbearing potential: must have undergone one of the following&#xD;
             sterilization procedures at least 6 months prior to the first dose:&#xD;
&#xD;
               -  hysteroscopic sterilization;&#xD;
&#xD;
               -  bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
               -  hysterectomy;&#xD;
&#xD;
               -  bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year&#xD;
                  prior to the first dose and follicle stimulating hormone (FSH) serum levels&#xD;
                  consistent with postmenopausal status.&#xD;
&#xD;
          7. A non vasectomized, male subject must agree to use a condom with spermicide or abstain&#xD;
             from sexual intercourse during the study until 90 days beyond the last dose of study&#xD;
             drug. (No restrictions are required for a vasectomized male provided his vasectomy has&#xD;
             been performed 4 months or more prior to first dose of study drug. A male who has been&#xD;
             vasectomized less than 4 months prior to study first dose must follow the same&#xD;
             restrictions as a non vasectomized male).&#xD;
&#xD;
          8. If male, must agree not to donate sperm from the first dose until 90 days after last&#xD;
             dosing.&#xD;
&#xD;
          9. No clinically significant history or presence of ECG findings as judged by the PI at&#xD;
             screening and check-in of Period 1, including each criterion as listed below:&#xD;
&#xD;
               -  Normal sinus rhythm (heart rate between 50 bpm and 100 bpm inclusive);&#xD;
&#xD;
               -  QTcF interval ≤ 450 msec;&#xD;
&#xD;
               -  QRS interval ≤ 110 msec; if &gt; 110 msec, result will be confirmed by a manual over&#xD;
                  read;&#xD;
&#xD;
               -  PR interval ≤ 220 msec.&#xD;
&#xD;
         10. Normal renal function (creatinine clearance from 80 to 180 mL/minute per&#xD;
             Cockcroft-Gault equation; 24-hour urinary creatinine collection may be used for&#xD;
             borderline cases).&#xD;
&#xD;
         11. PEF of ≥ 80% per handheld meter and oxygen saturation of ≥ 95% by pulse oximetry.&#xD;
&#xD;
         12. Understands the study procedures in the informed consent form (ICF), and be willing&#xD;
             and able to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is mentally or legally incapacitated or has significant emotional problems at&#xD;
             the time of the screening visit or expected during the conduct of the study.&#xD;
&#xD;
          2. History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the PI or designee.&#xD;
&#xD;
          3. History of any illness that, in the opinion of the PI or designee, might confound the&#xD;
             results of the study or poses an additional risk to the subject by their participation&#xD;
             in the study.&#xD;
&#xD;
          4. History or presence of alcoholism or drug abuse within the past 2 years prior to the&#xD;
             first dose.&#xD;
&#xD;
          5. History or presence of:&#xD;
&#xD;
               -  risk factors for Torsade de Pointes (e.g., heart failure, cardiomyopathy, or&#xD;
                  family history of Long QT Syndrome);&#xD;
&#xD;
               -  sick sinus syndrome, second or third degree atrioventricular block, myocardial&#xD;
                  infarction, pulmonary congestion, symptomatic or significant cardiac arrhythmia,&#xD;
                  prolonged QTcF interval, or conduction abnormalities.&#xD;
&#xD;
          6. Any acute or chronic pain conditions requiring ongoing treatment or limiting daily&#xD;
             activities.&#xD;
&#xD;
          7. History of fainting upon blood sampling or needle puncture.&#xD;
&#xD;
          8. Findings during the screening neurological examination that could interfere with or&#xD;
             preclude neurological assessments during the study, in the opinion of the PI or&#xD;
             designee.&#xD;
&#xD;
          9. History or presence of neurologic or neuromuscular disease.&#xD;
&#xD;
         10. Allergy to band aids, adhesive dressing or medical tape.&#xD;
&#xD;
         11. History or presence of hypersensitivity or idiosyncratic reaction to the study&#xD;
             drug(s), related compounds, or fish.&#xD;
&#xD;
         12. History of anaphylaxis to a medication, dietary item, or environment exposures&#xD;
             (including bee stings).&#xD;
&#xD;
         13. Female subjects with a positive pregnancy test or lactating.&#xD;
&#xD;
         14. Positive urine drug, cotinine, or alcohol results at screening or check in of Period&#xD;
             1.&#xD;
&#xD;
         15. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg) or hepatitis C virus (HCV).&#xD;
&#xD;
         16. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
             screening.&#xD;
&#xD;
         17. Seated heart rate is lower than 50 bpm or higher than 99 bpm at screening.&#xD;
&#xD;
         18. Unable to refrain from or anticipates the use of any drug, including prescription and&#xD;
             non prescription medications, herbal remedies, or vitamin supplements beginning 14&#xD;
             days prior to the first dose and throughout the study.&#xD;
&#xD;
         19. Has been on a diet incompatible with the on study diet, in the opinion of the PI or&#xD;
             designee, within the 30 days prior to the first dose and throughout the study.&#xD;
&#xD;
         20. Donation of blood or significant blood loss within 56 days prior to the first dose.&#xD;
&#xD;
         21. Plasma donation within 7 days prior to the first dose.&#xD;
&#xD;
         22. Participation in another clinical study within 30 days prior to the first dose. The 30&#xD;
             day window will be derived from the date of the last blood collection or dosing,&#xD;
             whichever is later, in the previous study to Day 1 of Period 1 of the current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TQT TTX Halneuron cardiac safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetrodotoxin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

